Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Molecular dynamics investigation on the poor sensitivity of A171T mutant NEDD8-activating enzyme (NAE) for MLN4924.

Verma S, Singh A, Mishra A.

J Biomol Struct Dyn. 2014;32(7):1064-73. doi: 10.1080/07391102.2013.804436. Epub 2013 Jun 20.

PMID:
23782099
2.

A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924.

Toth JI, Yang L, Dahl R, Petroski MD.

Cell Rep. 2012 Apr 19;1(4):309-16. doi: 10.1016/j.celrep.2012.02.006. Epub 2012 Mar 19.

3.

Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells.

Xu GW, Toth JI, da Silva SR, Paiva SL, Lukkarila JL, Hurren R, Maclean N, Sukhai MA, Bhattacharjee RN, Goard CA, Medeiros B, Gunning PT, Dhe-Paganon S, Petroski MD, Schimmer AD.

PLoS One. 2014 Apr 1;9(4):e93530. doi: 10.1371/journal.pone.0093530. eCollection 2014. Erratum in: PLoS One. 2014;9(10):e112004. Medeiros, Bruno [added].

4.

Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.

Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, Soucy TA, Milhollen MA, Yang X, Burkhardt AL, Ma J, Loke HK, Lingaraj T, Wu D, Hamman KB, Spelman JJ, Cullis CA, Langston SP, Vyskocil S, Sells TB, Mallender WD, Visiers I, Li P, Claiborne CF, Rolfe M, Bolen JB, Dick LR.

Mol Cell. 2010 Jan 15;37(1):102-11. doi: 10.1016/j.molcel.2009.12.024.

5.

Molecular dynamics simulation on the low sensitivity of mutants of NEDD-8 activating enzyme for MLN4924 inhibitor as a cancer drug.

Rashidieh B, Valizadeh M, Assadollahi V, Ranjbar MM.

Am J Cancer Res. 2015 Oct 15;5(11):3400-6. eCollection 2015.

6.

Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen.

Yan ZH, Burkhardt A, Loke HK, Chen J, Xu Q, Brauer P, Ma J, Lin Y, Garcia K, Dick LR, Bembenek ME.

Anal Biochem. 2013 Aug 15;439(2):109-15. doi: 10.1016/j.ab.2013.04.016. Epub 2013 Apr 25.

PMID:
23624319
7.

Absolute quantification of E1, ubiquitin-like proteins and Nedd8-MLN4924 adduct by mass spectrometry.

Yang X, Brownell JE, Xu Q, Zhu F, Ma J, Loke HK, Rollins N, Soucy TA, Minissale JJ, Thomas MP, Mallender WD, Dick LR, Li P, Liao H.

Cell Biochem Biophys. 2013 Sep;67(1):139-47. doi: 10.1007/s12013-013-9625-5.

PMID:
23754621
8.

Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.

Milhollen MA, Thomas MP, Narayanan U, Traore T, Riceberg J, Amidon BS, Bence NF, Bolen JB, Brownell J, Dick LR, Loke HK, McDonald AA, Ma J, Manfredi MG, Sells TB, Sintchak MD, Yang X, Xu Q, Koenig EM, Gavin JM, Smith PG.

Cancer Cell. 2012 Mar 20;21(3):388-401. doi: 10.1016/j.ccr.2012.02.009.

9.

Structure-based repurposing of FDA-approved drugs as inhibitors of NEDD8-activating enzyme.

Zhong HJ, Liu LJ, Chan DS, Wang HM, Chan PW, Ma DL, Leung CH.

Biochimie. 2014 Jul;102:211-5. doi: 10.1016/j.biochi.2014.03.005. Epub 2014 Mar 19.

PMID:
24657219
10.

Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924.

Liao H, Liu XJ, Blank JL, Bouck DC, Bernard H, Garcia K, Lightcap ES.

Mol Cell Proteomics. 2011 Nov;10(11):M111.009183. doi: 10.1074/mcp.M111.009183. Epub 2011 Aug 26.

11.

Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways.

Garcia K, Blank JL, Bouck DC, Liu XJ, Sappal DS, Hather G, Cosmopoulos K, Thomas MP, Kuranda M, Pickard MD, Liu R, Bandi S, Smith PG, Lightcap ES.

Mol Cancer Ther. 2014 Jun;13(6):1625-35. doi: 10.1158/1535-7163.MCT-13-0634. Epub 2014 Mar 26.

13.

Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues.

Chen JJ, Tsu CA, Gavin JM, Milhollen MA, Bruzzese FJ, Mallender WD, Sintchak MD, Bump NJ, Yang X, Ma J, Loke HK, Xu Q, Li P, Bence NF, Brownell JE, Dick LR.

J Biol Chem. 2011 Nov 25;286(47):40867-77. doi: 10.1074/jbc.M111.279984. Epub 2011 Oct 3.

14.

MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.

Nawrocki ST, Griffin P, Kelly KR, Carew JS.

Expert Opin Investig Drugs. 2012 Oct;21(10):1563-73. Epub 2012 Jul 16. Review.

PMID:
22799561
15.

Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.

Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H, Tayber O, Hather G, Liu R, Narayanan U, Milhollen MA, Lightcap ES.

Cancer Res. 2013 Jan 1;73(1):225-34. doi: 10.1158/0008-5472.CAN-12-1729. Epub 2012 Oct 24.

16.

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.

Gu Y, Kaufman JL, Bernal L, Torre C, Matulis SM, Harvey RD, Chen J, Sun SY, Boise LH, Lonial S.

Blood. 2014 May 22;123(21):3269-76. doi: 10.1182/blood-2013-08-521914. Epub 2014 Apr 8.

17.

High Efficiency Apoptosis Induction in Breast Cancer Cell Lines by MLN4924/2DG Co-Treatment.

Oladghaffari M, Islamian JP, Baradaran B, Monfared AS, Farajollahi A, Shanehbandi D, Mohammadi M.

Asian Pac J Cancer Prev. 2015;16(13):5471-6.

18.

The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.

Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D, Pan Y, Ding C, Qian J, Wu L, Chu Y, Yi J, Wang X, Sun Y, Jeong LS, Liu J, Jia L.

Cancer Res. 2012 Jul 1;72(13):3360-71. doi: 10.1158/0008-5472.CAN-12-0388. Epub 2012 May 4.

19.

Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.

Wei D, Li H, Yu J, Sebolt JT, Zhao L, Lawrence TS, Smith PG, Morgan MA, Sun Y.

Cancer Res. 2012 Jan 1;72(1):282-93. doi: 10.1158/0008-5472.CAN-11-2866. Epub 2011 Nov 9.

20.

A first-in-class NAE inhibitor, MLN4924, blocks lentiviral infection in myeloid cells by disrupting neddylation-dependent Vpx-mediated SAMHD1 degradation.

Wei W, Guo H, Liu X, Zhang H, Qian L, Luo K, Markham RB, Yu XF.

J Virol. 2014 Jan;88(1):745-51. doi: 10.1128/JVI.02568-13. Epub 2013 Oct 23.

Supplemental Content

Support Center